{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:05:32Z","timestamp":1779807932746,"version":"3.53.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. BCL2 overexpression has been related to a higher risk of GVHD and glucocorticoid resistance. In this study, we aimed to evaluate the role of BCL2 in GVHD pathophysiology. Remarkably, we observed that the pharmacological inhibition of BCL2 increased the risk of GVHD in murine models. In addition, we used a GVHD model with C57BL\/6 donor mice that constitutively overexpress human BCL2 gene in hematopoietic cells (Vav-BCL2). Interestingly, the overexpression of BCL2 in donor lymphocytes was related to a lower risk and severity of GVHD. In vitro, the BCL2 inhibitor venetoclax significantly hampered resting T-cell viability, but it did not affect activated lymphocytes, at least in part because of reduced BCL2 interacting mediator of cell death\u2013BCL2 binding after activation. Moreover, BCL2 overexpressing T cells had compromised functionality. Overexpression of BCL2 had no deleterious effect on graft-versus-leukemia activity. Finally, in vitro studies showed that exposure to steroids enriched the populations of T cells displaying higher BCL2 expression levels. Therefore, our study shows that high expression of BCL2 decreases the risk and severity of GVHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017700","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:30:33Z","timestamp":1774989033000},"page":"3572-3586","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["<i>BCL2<\/i>\n                    overexpression in donor lymphocytes reduces the risk of graft-versus-host disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8852-1465","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Bejarano-Garc\u00eda","sequence":"first","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Nufer","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Palacios-Barea","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Guijarro-Albaladejo","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Bella","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2781-440X","authenticated-orcid":false,"given":"Cristian","family":"Robles-Ben\u00edtez","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-9860","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0825-1714","authenticated-orcid":false,"given":"Inmaculada","family":"Carrasco-Brocal","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Lara-Chica","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-7793","authenticated-orcid":false,"given":"Luzalba","family":"Sanoja-Flores","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8254-2266","authenticated-orcid":false,"given":"Nicolas Valerdiz","family":"Mendendez","sequence":"additional","affiliation":[{"name":"2Department of Pathological Anatomy, Hospital Universitario Virgen del Roc\u00edo, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-3793","authenticated-orcid":false,"given":"Teresa","family":"Caballero-Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"3Department of Haematology, Hospital Universitario Virgen del Roc\u00edo, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-077X","authenticated-orcid":false,"given":"Alfonso","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[{"name":"1Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"},{"name":"3Department of Haematology, Hospital Universitario Virgen del Roc\u00edo, Campus Universitario Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026052610375169400_bib1","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"issue":"1","key":"2026052610375169400_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2026052610375169400_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease \u2014 biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026052610375169400_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.15719","article-title":"Developing role of B cells in the pathogenesis and treatment of chronic GVHD","volume":"184","author":"Li","year":"2019","journal-title":"Br J Haematol"},{"issue":"24","key":"2026052610375169400_bib5","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2008-10-161638","article-title":"The role of B cells in the pathogenesis of graft-versus-host disease","volume":"114","author":"Shimabukuro-Vornhagen","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2026052610375169400_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.humimm.2019.03.003","article-title":"B cells in chronic graft-versus-host disease","volume":"80","author":"McManigle","year":"2019","journal-title":"Hum Immunol"},{"issue":"2","key":"2026052610375169400_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2026052610375169400_bib8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3324\/haematol.2014.104166","article-title":"Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Murase","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"2026052610375169400_bib9","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.jid.2020.02.029","article-title":"Anti-apoptotic molecule BCL2 is a therapeutic target in steroid-refractory graft-versus-host disease","volume":"140","author":"Strobl","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2026052610375169400_bib10","doi-asserted-by":"crossref","first-page":"8348","DOI":"10.1038\/s41598-022-12407-x","article-title":"Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib","volume":"12","author":"Rodr\u00edguez-Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"2026052610375169400_bib11","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.173.9.5467","article-title":"Target antigens determine graft-versus-host disease phenotype","volume":"173","author":"Kaplan","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"2026052610375169400_bib12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5858\/arpa.2015-0187-OA","article-title":"Clinicopathologic threshold of acute colorectal graft-versus-host disease","volume":"140","author":"Gomez","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"2026052610375169400_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","article-title":"NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report","volume":"21","author":"Shulman","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026052610375169400_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ijc.30483","article-title":"Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo","volume":"140","author":"Barbado","year":"2017","journal-title":"Int J Cancer"},{"issue":"11","key":"2026052610375169400_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","article-title":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells","volume":"12","author":"Ludwig","year":"2021","journal-title":"Cell Death Dis"},{"issue":"5","key":"2026052610375169400_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/cdd.2017.30","article-title":"Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo","volume":"24","author":"Carrington","year":"2017","journal-title":"Cell Death Differ"},{"issue":"DEC","key":"2026052610375169400_bib17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2017.01809","article-title":"Life and death of activated T cells: how are they different from na\u00efve T cells?","volume":"8","author":"Zhan","year":"2017","journal-title":"Front Immunol"},{"issue":"13","key":"2026052610375169400_bib18","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026052610375169400_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/eji.201646574","article-title":"B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients","volume":"47","author":"Marasco","year":"2017","journal-title":"Eur J Immunol"},{"issue":"26","key":"2026052610375169400_bib20","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.96.26.14943","article-title":"Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival","volume":"96","author":"Ogilvy","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"MAY","key":"2026052610375169400_bib21","article-title":"Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity","volume":"9","author":"Gnanaprakasam","year":"2018","journal-title":"Front Immunol"},{"issue":"Part A","key":"2026052610375169400_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mito.2014.06.002","article-title":"Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS regulator","volume":"19 pt A","author":"Chong","year":"2014","journal-title":"Mitochondrion"},{"issue":"12","key":"2026052610375169400_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.freeradbiomed.2004.03.023","article-title":"Regulation of T-cell apoptosis by reactive oxygen species [preprint]","volume":"36","author":"Hildeman","year":"2004","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"2026052610375169400_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1074-7613(00)80072-2","article-title":"Reactive oxygen species regulate activation-induced T cell apoptosis","volume":"10","author":"Hildeman","year":"1999","journal-title":"Immunity"},{"issue":"6907","key":"2026052610375169400_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nature01101","article-title":"Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c\/Apaf-1\/caspase-9 apoptosome","volume":"419","author":"Marsden","year":"2002","journal-title":"Nature"},{"issue":"8","key":"2026052610375169400_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis"},{"issue":"12","key":"2026052610375169400_bib27","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41409-021-01452-1","article-title":"Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease","volume":"56","author":"Ramos","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1-2","key":"2026052610375169400_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J Immunol Methods"},{"key":"2026052610375169400_bib29","article-title":"Simultaneous detection of murine antigen-specific intracellular cytokines and CD107a\/CD107b by flow cytometry","author":"Ruitenberg","year":"2007","journal-title":"Protoc Exch"},{"issue":"1","key":"2026052610375169400_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T cell apoptosis and function","volume":"63","author":"Herold","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2026052610375169400_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2026052610375169400_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","article-title":"The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages","volume":"181","author":"Dzhagalov","year":"2008","journal-title":"J Immunol"},{"issue":"8","key":"2026052610375169400_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/cdd.2013.55","article-title":"Guarding effector T-cell survival: all for one, Mcl-1 for all","volume":"20","author":"Ottina","year":"2013","journal-title":"Cell Death Differ"},{"issue":"7","key":"2026052610375169400_bib34","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41409-021-01245-6","article-title":"Venetoclax does not impair activated T-cell proliferation","volume":"56","author":"Siblany","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"6626","key":"2026052610375169400_bib35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/386728a0","article-title":"Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2 Futoshi Shibasaki, Eisaku Kondo","volume":"386","author":"Shibasaki","year":"1997","journal-title":"Nature"},{"issue":"6","key":"2026052610375169400_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-7613(02)00322-9","article-title":"Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member Bim","volume":"16","author":"Hildeman","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"2026052610375169400_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell\u2013mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026052610375169400_bib38","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41418-023-01232-y","article-title":"The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation","volume":"30","author":"Liu","year":"2023","journal-title":"Cell Death Differ"},{"issue":"24","key":"2026052610375169400_bib39","doi-asserted-by":"crossref","first-page":"e0173022","DOI":"10.1128\/jvi.01730-22","article-title":"The BCL-2 inhibitor venetoclax augments immune effector function mediated by Fas ligand, TRAIL, and perforin\/granzyme B, resulting in reduced plasma viremia and decreased HIV reservoir size during acute HIV infection in a humanized mouse model","volume":"96","author":"Chandrasekar","year":"2022","journal-title":"J Virol"},{"issue":"4","key":"2026052610375169400_bib40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2026052610375169400_bib41","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"issue":"3","key":"2026052610375169400_bib42","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment [preprint]","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int J Hematol"},{"issue":"2","key":"2026052610375169400_bib43","first-page":"e53655","article-title":"Successful treatment with venetoclax plus azacytidine combined with radiation therapy and donor lymphocyte infusion in a patient with extramedullary relapse of acute myeloid leukemia after stem cell transplantation","volume":"16","author":"Shirato","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"2026052610375169400_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2026052610375169400_bib45","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/s41409-021-01439-y","article-title":"Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial","volume":"56","author":"Malladi","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026052610375169400_bib46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-024-44703-7","article-title":"ROCK1\/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease","volume":"15","author":"Maas-Bauer","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026052610375169400_bib47","doi-asserted-by":"crossref","first-page":"12475","DOI":"10.1038\/s41598-018-30814-x","article-title":"Murine models of steroid refractory graft-versus-host disease","volume":"8","author":"Toubai","year":"2018","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3572\/2519621\/blooda_adv-2025-017700-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3572\/2519621\/blooda_adv-2025-017700-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:38:04Z","timestamp":1779806284000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3572\/567500\/BCL2-overexpression-in-donor-lymphocytes-reduces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017700","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}